⌕
Bioventus · BVS · Nasdaq
Tenet 56 · Mixed
Compare
$10.60+1.34%At closeTenet 56 · Mixed
$10.60+0.14 (+1.34%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Bioventus (BVS) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue fell 0.9% in FY25, net margin 4.0%, and free cash flow (~$72.1M) tracks net income. Earnings are cash, not paper. Worth your attention in FY25: Share count (+51.6%) and Capex step-up ($2.6M). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▼0.9%
568.1
FY21→FY25CAGR +7.2%/yr
Net income ($M)—
22.7
one-off year: see footnoteCAGR +4.1%/yr
Free cash flow ($M)▲90.8%
72.1
capex stepped upCAGR +66.1%/yr
Diluted EPS—
0.33
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+51.6%

45.5mn → 68.9mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex step-up
$2.6M

▲155% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)568.1Revenue−179.9COGS388.2Gross profit−12.1R&D−314.0SG&A54.0Op income−31.2Tax & other22.7Net income

4¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
806040200%sector median net margin ~3%FY21FY25

Over this window: gross 70.3% → 68.3%. Net margin 4.0% is above the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
585,639.0568,087.0573,280.0512,345.0512,117.0430,898.0▼0.9%+7.2%
Cost of revenue
183,294.0179,930.0185,054.0184,152.0181,037.0128,192.0▼2.8%+8.8%
Gross profit
402,345.0388,157.0388,226.0328,193.0331,080.0302,706.0▼0.0%+6.4%
Research & development
12,082.012,113.013,951.013,446.023,854.019,039.0▼13.2%−10.7%
Selling, general & admin
326,767.0314,026.0343,798.0303,879.0332,134.0254,253.0▼8.7%+5.4%
Total operating expenses
345,616.0334,182.0403,421.0409,918.0498,314.0290,645.0▼17.2%+3.6%
Operating incomefeeds ROC rank
56,729.053,975.0−15,195.0−81,725.0−167,234.012,061.0—+45.4%
Other income, net
−16,603.0−28,266.0−37,147.0−39,386.0−21,791.0−2,573.0——
Pretax income
40,126.025,709.0−52,342.0−121,111.0−189,025.09,488.0—+28.3%
Income tax
−24,202.0−1,565.0−5,293.085.0−44,374.0−1,966.0▲70.4%—
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings
57,296.022,732.0−36,125.0−156,230.0−158,704.019,375.0—+4.1%
Per share
Diluted EPSbuyback-sensitive
0.800.33−0.56−2.49−2.59−0.15——
Diluted shares (mn)
72.4968.9164.5562.6561.3945.47▲6.8%+11.0%
Margins
Gross margin54th pct in Healthcare
68.7%68.3%67.7%64.1%64.6%70.3%▲0.6pp−1.9pp
Operating margin
9.7%9.5%−2.7%−16.0%−32.7%2.8%▲12.2pp+6.7pp
Net margin67th pct in Healthcare
9.8%4.0%−6.3%−30.5%−31.0%4.5%▲10.3pp−0.5pp
† TTM = trailing four quarters through 2026-09-26.FY21 effective tax rate was −21% vs a −0% norm for this window, likely a one-time item; see the filing.FY22 effective tax rate was 23% vs a −0% norm for this window, likely a one-time item; see the filing.
FY19 – FY20 · 2 more years
Unlock the full history →
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-05 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Bioventus' revenue last fiscal year?

Bioventus reported revenue of $568.1M in fiscal 2025, down 0.9% from fiscal 2024.

What was Bioventus' net income?

Bioventus reported net income of $22.7M in fiscal 2025, a net margin of 4.0%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.